N Petrucelli, MB Daly, T Pal - 2022 - europepmc.org
BRCA1-and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer …
S Yadav, NJ Boddicker, J Na, EC Polley… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 …
N Mavaddat, S Peock, D Frost, S Ellis… - JNCI: Journal of the …, 2013 - academic.oup.com
Background Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRCA2 mutation carriers. The aims of this study were to derive penetrance estimates for …
D Cragun, A Weidner, C Lewis, D Bonner, J Kim… - Cancer, 2017 - Wiley Online Library
BACKGROUND Breast cancer (BC) disparities may widen with genomic advances. The authors compared non‐Hispanic white (NHW), black, and Hispanic BC survivors for 1) …
I Bedrosian, MR Somerfield, MI Achatz… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …
Recent advances in radiotherapy have enabled the use of different types of particles, such as protons and heavy ions, as well as refinements to the treatment of tumours with standard …
K Metcalfe, S Gershman, HT Lynch, P Ghadirian… - British journal of …, 2011 - nature.com
Purpose: The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and …
A Valachis, AD Nearchou, P Lind - Breast cancer research and treatment, 2014 - Springer
This meta-analysis investigates the oncological safety of breast-conserving therapy BCT in BRCA-mutation carriers and the risk for contralateral breast cancer (CBC) compared with …
KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of clinical …, 2013 - ascopubs.org
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …